Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens With Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women With Locally Advanced HER2-Negative Breast Cancer

NCT01705691 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT01705691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01705691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens With Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women With Locally Advanced HER2-Negative Breast Cancer
Lead sponsor
NSABP Foundation Inc
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2012
Completion date
October 31, 2015
Enrollment
50 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2-negative breast cancer